HALEON PLC-ADR (HLN) Fundamental Analysis & Valuation

NYSE:HLN • US4055521003

10.03 USD
-0.04 (-0.4%)
At close: Mar 13, 2026
10.02 USD
-0.01 (-0.1%)
After Hours: 3/13/2026, 10:31:02 PM

This HLN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to HLN. HLN was compared to 193 industry peers in the Pharmaceuticals industry. While HLN has a great profitability rating, there are some minor concerns on its financial health. HLN has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

8

1. HLN Profitability Analysis

1.1 Basic Checks

  • HLN had positive earnings in the past year.
  • HLN had a positive operating cash flow in the past year.
  • Each year in the past 5 years HLN has been profitable.
  • HLN had a positive operating cash flow in each of the past 5 years.
HLN Yearly Net Income VS EBIT VS OCF VS FCFHLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

1.2 Ratios

  • HLN's Return On Assets of 5.11% is amongst the best of the industry. HLN outperforms 86.53% of its industry peers.
  • The Return On Equity of HLN (10.15%) is better than 85.49% of its industry peers.
  • HLN's Return On Invested Capital of 6.91% is amongst the best of the industry. HLN outperforms 84.97% of its industry peers.
Industry RankSector Rank
ROA 5.11%
ROE 10.15%
ROIC 6.91%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HLN Yearly ROA, ROE, ROICHLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 2 4 6 8

1.3 Margins

  • The Profit Margin of HLN (15.11%) is better than 88.08% of its industry peers.
  • In the last couple of years the Profit Margin of HLN has grown nicely.
  • HLN has a better Operating Margin (22.36%) than 89.64% of its industry peers.
  • HLN's Operating Margin has been stable in the last couple of years.
  • HLN has a better Gross Margin (64.69%) than 73.58% of its industry peers.
  • HLN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 22.36%
PM (TTM) 15.11%
GM 64.69%
OM growth 3Y-0.1%
OM growth 5Y0.08%
PM growth 3Y15.68%
PM growth 5Y5.48%
GM growth 3Y1.46%
GM growth 5Y0.97%
HLN Yearly Profit, Operating, Gross MarginsHLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 20 40 60

4

2. HLN Health Analysis

2.1 Basic Checks

  • HLN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • HLN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
HLN Yearly Shares OutstandingHLN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B
HLN Yearly Total Debt VS Total AssetsHLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

  • An Altman-Z score of 2.51 indicates that HLN is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • HLN's Altman-Z score of 2.51 is fine compared to the rest of the industry. HLN outperforms 66.32% of its industry peers.
  • The Debt to FCF ratio of HLN is 3.88, which is a good value as it means it would take HLN, 3.88 years of fcf income to pay off all of its debts.
  • HLN has a Debt to FCF ratio of 3.88. This is amongst the best in the industry. HLN outperforms 88.08% of its industry peers.
  • A Debt/Equity ratio of 0.47 indicates that HLN is not too dependend on debt financing.
  • HLN has a Debt to Equity ratio of 0.47. This is in the lower half of the industry: HLN underperforms 61.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 3.88
Altman-Z 2.51
ROIC/WACC0.75
WACC9.21%
HLN Yearly LT Debt VS Equity VS FCFHLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.3 Liquidity

  • HLN has a Current Ratio of 0.92. This is a bad value and indicates that HLN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • HLN has a Current ratio of 0.92. This is amonst the worse of the industry: HLN underperforms 85.49% of its industry peers.
  • A Quick Ratio of 0.71 indicates that HLN may have some problems paying its short term obligations.
  • HLN has a Quick ratio of 0.71. This is amonst the worse of the industry: HLN underperforms 83.94% of its industry peers.
Industry RankSector Rank
Current Ratio 0.92
Quick Ratio 0.71
HLN Yearly Current Assets VS Current LiabilitesHLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

3

3. HLN Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 6.59% over the past year.
  • Measured over the past years, HLN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 17.56% on average per year.
  • HLN shows a decrease in Revenue. In the last year, the revenue decreased by -0.61%.
  • HLN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.78% yearly.
EPS 1Y (TTM)6.59%
EPS 3Y1.58%
EPS 5Y17.56%
EPS Q2Q%281.35%
Revenue 1Y (TTM)-0.61%
Revenue growth 3Y5.58%
Revenue growth 5Y5.78%
Sales Q2Q%-0.29%

3.2 Future

  • Based on estimates for the next years, HLN will show a small growth in Earnings Per Share. The EPS will grow by 7.38% on average per year.
  • HLN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.26% yearly.
EPS Next Y6.33%
EPS Next 2Y8.54%
EPS Next 3Y8.95%
EPS Next 5Y7.38%
Revenue Next Year-1.37%
Revenue Next 2Y1.08%
Revenue Next 3Y2.23%
Revenue Next 5Y3.26%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
HLN Yearly Revenue VS EstimatesHLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
HLN Yearly EPS VS EstimatesHLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.1 0.2 0.3 0.4 0.5

6

4. HLN Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 20.90, the valuation of HLN can be described as rather expensive.
  • 81.35% of the companies in the same industry are more expensive than HLN, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of HLN to the average of the S&P500 Index (25.70), we can say HLN is valued inline with the index average.
  • Based on the Price/Forward Earnings ratio of 17.66, the valuation of HLN can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of HLN indicates a rather cheap valuation: HLN is cheaper than 81.35% of the companies listed in the same industry.
  • HLN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.84.
Industry RankSector Rank
PE 20.9
Fwd PE 17.66
HLN Price Earnings VS Forward Price EarningsHLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HLN indicates a rather cheap valuation: HLN is cheaper than 82.90% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, HLN is valued cheaply inside the industry as 87.05% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 15.02
EV/EBITDA 14.43
HLN Per share dataHLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates HLN does not grow enough to justify the current Price/Earnings ratio.
  • HLN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)3.3
PEG (5Y)1.19
EPS Next 2Y8.54%
EPS Next 3Y8.95%

5

5. HLN Dividend Analysis

5.1 Amount

  • HLN has a Yearly Dividend Yield of 1.86%.
  • HLN's Dividend Yield is rather good when compared to the industry average which is at 0.71. HLN pays more dividend than 92.23% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, HLN has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 1.86%

5.2 History

  • HLN has paid a dividend for at least 10 years, which is a reliable track record.
  • HLN has decreased its dividend recently.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
HLN Yearly Dividends per shareHLN Yearly Dividends per shareYearly Dividends per share 2023 2024 2025 2026 0.05 0.1 0.15 0.2

5.3 Sustainability

  • HLN pays out 36.71% of its income as dividend. This is a sustainable payout ratio.
DP36.71%
EPS Next 2Y8.54%
EPS Next 3Y8.95%
HLN Yearly Income VS Free CF VS DividendHLN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B
HLN Dividend Payout.HLN Dividend Payout, showing the Payout Ratio.HLN Dividend Payout.PayoutRetained Earnings

HLN Fundamentals: All Metrics, Ratios and Statistics

HALEON PLC-ADR

NYSE:HLN (3/13/2026, 10:31:02 PM)

After market: 10.02 -0.01 (-0.1%)

10.03

-0.04 (-0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-25
Earnings (Next)04-29
Inst Owners60.22%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap44.66B
Revenue(TTM)11.23B
Net Income(TTM)1.67B
Analysts80
Price Target11.91 (18.74%)
Short Float %0.42%
Short Ratio2.21
Dividend
Industry RankSector Rank
Dividend Yield 1.86%
Yearly Dividend0.17
Dividend Growth(5Y)N/A
DP36.71%
Div Incr Years1
Div Non Decr Years1
Ex-Date04-10
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.73%
Min Revenue beat(2)-3.78%
Max Revenue beat(2)-1.69%
Revenue beat(4)0
Avg Revenue beat(4)-3.44%
Min Revenue beat(4)-4.82%
Max Revenue beat(4)-1.69%
Revenue beat(8)0
Avg Revenue beat(8)-3.28%
Revenue beat(12)1
Avg Revenue beat(12)-2.85%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.16%
PT rev (3m)4.29%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.98%
EPS NY rev (3m)-1.41%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.08%
Revenue NY rev (3m)-1.08%
Valuation
Industry RankSector Rank
PE 20.9
Fwd PE 17.66
P/S 3.02
P/FCF 15.02
P/OCF 12.66
P/B 2.03
P/tB N/A
EV/EBITDA 14.43
EPS(TTM)0.48
EY4.79%
EPS(NY)0.57
Fwd EY5.66%
FCF(TTM)0.67
FCFY6.66%
OCF(TTM)0.79
OCFY7.9%
SpS3.32
BVpS4.94
TBVpS-2.76
PEG (NY)3.3
PEG (5Y)1.19
Graham Number7.3
Profitability
Industry RankSector Rank
ROA 5.11%
ROE 10.15%
ROCE 8.9%
ROIC 6.91%
ROICexc 7.26%
ROICexgc 251.94%
OM 22.36%
PM (TTM) 15.11%
GM 64.69%
FCFM 20.14%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-0.1%
OM growth 5Y0.08%
PM growth 3Y15.68%
PM growth 5Y5.48%
GM growth 3Y1.46%
GM growth 5Y0.97%
F-Score8
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 3.88
Debt/EBITDA 2.75
Cap/Depr 114.72%
Cap/Sales 3.74%
Interest Coverage 6.91
Cash Conversion 93.21%
Profit Quality 133.23%
Current Ratio 0.92
Quick Ratio 0.71
Altman-Z 2.51
F-Score8
WACC9.21%
ROIC/WACC0.75
Cap/Depr(3y)107.2%
Cap/Depr(5y)109.42%
Cap/Sales(3y)3.18%
Cap/Sales(5y)3.14%
Profit Quality(3y)146.3%
Profit Quality(5y)135.74%
High Growth Momentum
Growth
EPS 1Y (TTM)6.59%
EPS 3Y1.58%
EPS 5Y17.56%
EPS Q2Q%281.35%
EPS Next Y6.33%
EPS Next 2Y8.54%
EPS Next 3Y8.95%
EPS Next 5Y7.38%
Revenue 1Y (TTM)-0.61%
Revenue growth 3Y5.58%
Revenue growth 5Y5.78%
Sales Q2Q%-0.29%
Revenue Next Year-1.37%
Revenue Next 2Y1.08%
Revenue Next 3Y2.23%
Revenue Next 5Y3.26%
EBIT growth 1Y-3.1%
EBIT growth 3Y0.42%
EBIT growth 5Y2.28%
EBIT Next Year20.78%
EBIT Next 3Y10.91%
EBIT Next 5Y9.2%
FCF growth 1Y12%
FCF growth 3Y8.58%
FCF growth 5Y15.32%
OCF growth 1Y14.47%
OCF growth 3Y8.49%
OCF growth 5Y13.36%

HALEON PLC-ADR / HLN FAQ

Can you provide the ChartMill fundamental rating for HALEON PLC-ADR?

ChartMill assigns a fundamental rating of 5 / 10 to HLN.


Can you provide the valuation status for HALEON PLC-ADR?

ChartMill assigns a valuation rating of 6 / 10 to HALEON PLC-ADR (HLN). This can be considered as Fairly Valued.


How profitable is HALEON PLC-ADR (HLN) stock?

HALEON PLC-ADR (HLN) has a profitability rating of 8 / 10.


Can you provide the PE and PB ratios for HLN stock?

The Price/Earnings (PE) ratio for HALEON PLC-ADR (HLN) is 20.9 and the Price/Book (PB) ratio is 2.03.


Can you provide the dividend sustainability for HLN stock?

The dividend rating of HALEON PLC-ADR (HLN) is 5 / 10 and the dividend payout ratio is 36.71%.